Introduction
Standard treatment strategy for patients with advanced epithelial ovarian cancer consists of optimal cytoreductive surgery, preferably to lesions less than 1 cm, followed by cisplatin-based chemotherapy [1] . Approximately 70% of patients with stage III and IV ovarian carcinoma will respond, with a pathologically confirmed complete response in 20%-30% of cases [2] [3] [4] . Despite this high response rate, the proportion of patients experiencing long-term survival is small, even for those with a pathologically confirmed complete response [4~6] . Continuation of standard chemotherapy beyond six to eight cycles of treatment is not considered as an effective way to improve the proportion of long-term survivors [7] . Therefore, approaches aiming at an increased drug exposure or a higher dose-intensity of chemotherapy receive growing interest in order to improve cure rate. So far, cisplatin appears to be the most active single agent in ovarian carcinoma. High-dose (200 mg/m 2 ) intravenous cisplatin can produce responses in patients not responding to standard doses of this drug, but is associated with prohibitive oto-and neurotoxicity [8] . Highdose carboplatin supported by autologous bone-marrow transplantation is similarly associated with considerable toxicity [9] . As in many ovarian cancer patients the disease remains confined to the peritoneal cavity, intraperitoneal (i.p.) chemotherapy has been applied as an alternative approach to increase drug exposure. The delivery of cytotoxic agents to the peritoneal cavity can lead to high drug concentrations intraperitoneally with at the same time less systemic toxicity. This approach has been pioneered by Howell et al. [10] . They exploited the pharmacologic advantage of intraperitoneally delivered cisplatin compared to systemic administration, whereas the nephrotoxicity of absorbed drug was reduced by the simultaneous intravenous administration of sodium thiosulphate. Since then, the efficacy and feasibility of cisplatin-based i.p. chemotherapy with or without the systemic use of sodium thiosulphate has been demonstrated by several groups [11] [12] [13] [14] [15] [16] .
The combined delivery of cisplatin and etoposide is attractive because of synergism between these two agents in experimental systems [17] . This synergism has been demonstrated also clinically in the treatment of small cell lung cancer, germ cell tumors, and ovarian carcinoma [11, [18] [19] [20] . Etoposide is not completely crossresistant with cisplatin in ovarian cancer [21, 22] . A clinically complete response after six courses of i.p. chemotherapy with cisplatin and etoposide was observed in 24 out of 37 assessable patients, who received this combination as a salvage treatment following cisplatin-based i.v. chemotherapy [23] . These encouraging results stimulated us to initiate a phase II trial with i.p. high-dose cisplatin plus etoposide with i.v. sodium thiosulphate in ovarian cancer patients with either a pathologically complete response or with minimal residual disease (MRD).
Patients and methods
Patients treated between 1989 and 1995 were included in this analysis. Eligible patients either received i.p. chemotherapy as a consolidation treatment (after having achieved a pathologically confirmed complete response) or as a salvage regimen (in case of persistent disease after first-line platinum-based chemotherapy or abdominal recurrences). Four courses were scheduled when treatment was administered for consolidation and six when administered as a salvage regimen. The maximum size of intraabdominal lesions at the start of i.p. chemotherapy had to be < 2 cm. Patients were excluded in case of detectable metastatic disease outside the peritoneal cavity, extensive intraabdominal adhesions, WHO performance status > 2, > 75 years of age, or organ function disturbances affecting the tolerance of i.p. chemotherapy. This was defined as WBC <3 x 1O 9 /1, platelets <100 x 1O 9 /1, serum creatinine > 125 umol/1 or creatinine clearance <40 ml/min, clinically important hearing loss, or neurotoxicity > grade 1. All patients considered eligible for the study had the possibility of i.p. chemotherapy discussed before surgery and had given informed consent. In case the inclusion criteria were met and i.p. treatment was technically feasible, a port-a-cath system for i.p. drug delivery was inserted during laparotomy.
CT-peritoneography was performed before the start of i.p. treatment in order to assess the adequacy of distribution of i.p. administered drugs. All patients received intravenous prehydration with 1000 ml NaCl 0.9% over three hours, starting three hours before i.p treatment The chemotherapy regimen consisted of etoposide 350 mg/m 2 i.p. dissolved in 500 ml NaCl 0.9%, followed by cisplatin 200 mg/m 2 i.p. dissolved in 1500 ml NaCl 0.9%, administered in total over two hours. All solutions for i.p. delivery were heated to 37 °C before the chemotherapeutic agents were added. Intraperitoneal fluids were drained after a dwell time of four hours and the amount of recollectable fluid recorded. was added in case vomiting was still severe. Courses were repeated at four-week intervals for a total number of four to six courses. CTperitoneography was repeated every second course. Treatment was postponed for one week m case of WBC count < 3.0 x 10 9 /l, platelet count < 100 x 10 9 /l, or serum creatinine > 150 umol/1 at the time of scheduled retreatment. No dose reductions were allowed, except a 25% reduction of the etoposide dose in case of grade >2 stomatitis. If treatment had to be postponed for more than three weeks, the patient went off study. Treatment was also discontinued in case of disease progression, patient refusal, catheter malfunction, major distribution disturbances of i.p. administered fluids as revealed by peritoneography, the development of clinical hearing loss, or neurotoxicity grade > 2. Surgical response evaluation via third-look laparotomy with removal of the port-a-cath was planned in patients being clinically free of disease at the end of treatment. A pathological complete response (pCR) at that time was defined as disappearance of all macroscopic and microscopic disease with negative biopsies of all suspicious lesions including those of sites previously known to be involved, negative intraperitoneal washings, and a serum CA125 level within normal limits. In case macroscopic disease was still present, but could be removed completely, and blind biopsies and peritoneal washings both were negative this was called a surgically converted complete response. A pathologically defined partial response (pPR) was defined as a reduction of the size of all measurable lesions of more than 50%, or a pathological complete response without normalization of the serum CA125 concentration. Microscopic disease denoted absence of macroscopic disease with tumor positive random biopsies or positive peritoneal washings. Stable disease (SD) was < 25% increase or < 50% decrease of measurable lesions for at least four weeks. Progressive disease designated an increase in size of > 25% of measurable disease or the occurrence of new lesions. Patients without measurable or evaluable disease at the time of cessation of i.p. treatment who had no surgical restaging, and those starting i.p. treatment as a consolidation regimen, were considered not assessable for response.
Survival evaluation was performed on an intention to treat basis and was calculated from the commencement of i.p. treatment to the time of death or censoring. The duration of complete and partial response has been calculated from the start of i.p. treatment until the documentation of progression. Freedom from progression dates from the first day of i.p. therapy to the date of documented progression or censoring. An increasing level of CA125 alone was not an endpoint of freedom from progression.
Toxicity was assessed prospectively for each treatment cycle and graded according to WHO criteria. Nausea and vomiting was graded as mild, moderate or severe. Audiography was performed prior to each treatment course. Normal hearing was defined as an average threshold decrease within the 250-8000 Hz range of < 15 db, moderate hearing loss as an average decrease of 15-30 db, and severe hearing loss as an average decrease of > 30 db. Patients were considered to have significant hearing loss if serial audiography showed a drop of 15 db or more in pure tone threshold in one ear or a drop of 10 db or more in both ears at one or more frequencies [24] .
Statistics. Survival curves were constructed using the KaplanMeier technique and statistical differences between curves were calculated using log rank tests. All indicated P-values are based on twosided significance tests.
Results
Twenty-nine patients were entered. Six patients received i.p. treatment as a consolidation regimen, 17 patients had incomplete response after first-line treatment, whereas six patients received the treatment because of recurrent disease (in two of them after two or more prior chemotherapy regimens). The first-line treatment included cisplatin-based regimens in 19 cases and carboplatin-based regimens in seven, whereas three patients had received both agents before. The response to first-line treatment was CR in eight patients (two of them developed recurrent disease), PR in 15 patients, SD in five patients, whereas in one patient the initial response was unclear from the available data. Patient characteristics and intervals between diagnosis and start of i.p. treatment are summarized in Table 1 . At initial diagnosis five patients were stage IV because of pleural effusion with positive cytology (one patient), resected umbilical metastasis (three patients, one of them also had resected inguinal nodes), or abdominal wall metastasis (one patient).
A total of 105 courses (median 3, range 1-6) were administered with a median interval of 28.5 days (maximum 35 days). Twelve patients completed scheduled treatment. In 17 patients treatment was prematurely stopped because of inflow obstruction and pocket formation around the catheter tip (five patients), maldistribution due to intraabdominal adhesions (two patients), bowel perforation (two patients), or other toxicities of 
Response to treatment and survival
Fifteen patients were assessable for response and their response data according to pretreatment tumor volume are presented in Table 2 . Response was based on surgical restaging in 12 patients. Three patients had clinical manifestations of disease progression. One of them developed inflow obstruction after the first course, and CT peritoneography revealed progressive disease in the upper abdomen, an area prevented from being perfused due to adhesions between colon and the abdominal wall. Another patient had new lesions on top of the vagina and in the laparotomy scar after the fifth course, the third one developed pleural effusion with positive cytology within two months after the second cycle, when treatment had been discontinued for renal toxicity. In total 14 patients were not assessable for response. Four of them received only one course of i.p treatment. Four patients had clinically no evidence of disease when they stopped treatment, but surgical restaging was not per- formed. Six patients received i.p. treatment as a consolidation regimen. Two of them underwent surgical restaging with pCR confirmed at third-look, whereas four patients had no signs of disease on CT scanning or physical examination, but did not undergo surgical restaging. CA125 levels before the start of i.p. treatment tended to be higher in nonresponders to treatment compared to responders, but the difference did not reach statistical significance (P = 0.07, r-test for unevenly distributed values). In total four out of nine responding patients had elevated CA125 levels prior to the start of i.p. treatment, compared to five out of six nonresponders. CA125 levels for the first three cycles of treatment are presented in Figure 1 . This figure also indicates that the i.p. administration itself did not lead to any significant rise of CA125 between courses. For all patients who started intraperitoneal chemotherapy the median freedom from progression was 616 days and the median survival 1065 days (Figure 2 ). Patients receiving three or more cycles of i.p. treatment had a significantly longer survival than those in whom treatment was interrupted before the third cycle (P < 0.025). Sixteen of the 23 patients receiving more than one course of i.p. treatment developed progression. The site of first recurrence included the abdominal cavity in 12 patients and occurred in extraabdominal sites only in three patients, whereas in one patient the site of progression was unknown. 
Toxicity of treatment
All patients were considered eligible for toxicity analysis. The most troublesome complication was the formation of intraabdominal adhesions, preventing further i.p. treatment in nine (31%) patients. Pocket formation around the catheter tip was heralded by inflow obstruction in five of them, and four of these patients also had mild to moderate abdominal pain. Outflow obstruction occurred in the majority of patients, and in only 33% of 102 cycles for which data were available it appeared possible to drain 500 ml of fluid or more. Indeed, severe adhesions at restaging laparotomy were present in 10 out of 14 patients who underwent this procedure, including both patients with bowel perforation. One of them died from septic peritonitis, the other one recovered from this complication. One patient developed ileus caused by adhesions 16 months after treatment while in complete response.
Despite vigorous antiemetic treatment, severe nausea and vomiting occurred in 51% of cycles and in one patient it was the main reason to refrain from further treatment. Leukopenia and thrombocytopenia ^ grade 3 were recorded in 30% and 6% of courses, respectively. However, none of the patients developed neutropenic fever. These treatment related toxicities are summarized in Table 3 . Two out of 13 patients with preexisting neurotoxicity discontinued treatment after the first and third course, respectively, because of worsening of symptoms. In total 16 patients (55%) developed renal toxicity, defined as a > 25% increase from pretreatment creatinine values at any time during treatment. Overall, however, serious renal toxicity has not been observed (Figure 3) . The two patients who stopped treatment because of renal toxicity had only a temporary rise of serum creatinine above 200 umol/1 (211 and 283 umol/1, respectively). The pretreatment serum creatinine levels were 134 and 102 umol/1 in these patients, respectively. Ototoxicity was never dose-limiting. Serial tone audiograms were available in 23 patients. Eight of them developed a significant audiographic hearing loss: two out of eight patients without preexisting hearing loss, three out of eight patients with a moderate, and three out of seven patients with a severe preexisting hearing loss experienced a significant detoriation.
Discussion
Intraperitoneal administration of chemotherapy has the theoretical advantage of achieving a high local drug concentration, while the systemic exposure, and therefore organ toxicity, is lower than after intravenous administration of a similar dose. However, without systemic administration of the protective agent sodium thiosulphate the dose of cisplatin that can be safely administered intraperitoneally in cisplatin-pretreated patients is approximately 100 mg/m 2 , with renal and neurotoxicity being the dose-limiting toxicities [16] . Only with concurrent intravenous administration of sodium thiosulphate the dose of i.p. cisplatin can be doubled to 200 mg/m 2 without a high incidence of severe neurotoxicity and nephrotoxicity. In agreement with previous reports, our data demonstrate the tolerability of such a regimen [14, 18, [23] [24] [25] . Contrary to intravenous administration of cisplatin, magnesium wasting, a common complication of cisplatin tubulopathy, was never a problem (data not shown). Clinical hearing loss may also be prevented by sodium thiosulphate. Audiographic hearing loss can be demonstrated in the majority of patients treated with intravenous cisplatin and the severity increases with short infusion time and higher cumulative dosages [26, 27] . The serial tone audiograms we obtained after each cycle of treatment show that the incidence of audiographic hearing loss compares favorably with the ototoxicity associated with intravenously administered cisplatin [27] , and as such confirm previous observations that clinical hearing loss during high-dose i.p. cisplatin treatment with sodium thiosulphate protection is infrequent [23] . In fact, animal experiments have shown that sodium thiosulphate was superior to fosfomycin, diethyldithiocarbamate and WR-2721 in ameliorating the ototoxicity of cisplatin [28] .
However, in addition to the systemic toxicity caused by the absorption of intraperitoneally delivered drugs over the peritoneal membrane, local toxicity related to the specific route of administration of the drugs may occur. Intra-abdominal infection has been observed in up to 8% of patients, although in our series this complication did not occur [29] . Abdominal pain has been frequently reported in conjunction with i.p. administration of doxorubicin, mitoxantrone, and paclitaxel [30] [31] [32] . In our experience, severe pain during administration was infrequent. Considerable problems, however, were caused by intraabdominal adhesions, which necessitated the interruption of treatment in nine patients and were probably responsible for bowel erosion by the catheter in two of them. Bowel perforation during insertion of the port-a-cath system has been reported previously [29] . The two cases of bowel perforations in our series were not related to the insertion technique, but became evident after a period of normal functioning of the catheter. In both patients dense adhesions were found during surgery and most probably these adhesions prevented the catheter from free-floating in the abdominal cavity, causing erosion of the bowel by constant pressure of the catheter. Only in one of the patients some degree of inflow obstruction and abdominal pain were noticed during the administration of the chemotherapy. Similar cases have been described before, but the overall incidence of this complication is low [33] . Although it is generally thought that the presence of significant abdominal adhesions potentially limit the efficacy of i.p. therapy, this may not be true for cases in which it is possible to lyse all adhesions [34] . We found CT-peritoneography a useful adjunct to assess the adequate exposure of the abdominal cavity to i.p. treatment. Only few studies have performed serial distribution assessments during i.p. therapy. Contrast studies revealed that the true pelvis and the subdiaphragmic spaces were most often excluded from being perfused [35] . Serial studies using CT-peritoneography did not disclose a uniform pattern, some patients showing worsening, others improvement of the distribution of contrast [15, 35] . Using scintigraphic peritoneography, the incidence of maldistribution appears to be higher, even in patients without residual disease [36, 37] . It can not be concluded from the available data from the literature, whether CT peritoneography is a risk factor for the formation of adhesions.
After the demonstration that patients with gross residual disease do not benefit from i.p. treatment, it is generally accepted that only patients with small residual lesions at the completion of the laparotomy preceding i.p. treatment are eligible for such treatment [38] . There exists growing notion that secondary aggressive debulking in itself may have a direct impact on the survival of ovarian cancer patients, either when used during firstline treatment or in case of relapse [39, 40] . Therefore, the efficacy of salvage i.p. treatment can not be properly assessed from non-randomized trials. Despite a response rate of 60% in 15 evaluable patients, including four pathologically confirmed complete responses, the number of patients who remained disease free for a long period of time was small. Our survival data suggest that effective i.v. salvage therapy for patients relapsing after i.p. treatment, including paclitaxel in 12 of them, may have had a significant influence on the overall survival duration. The suggestive evidence from a beneficial effect of i.p. treatment comes from our finding that patients who continued treatment for more than 2 cycles had a better overall survival than those in whom treat-ment had to be interrupted. It should be noted, however, that the superiority of i.p. over i.v. treatment has been questioned [41] . Randomized trials on the value of salvage i.p. treatment are lacking and the potential benefit of i.p. treatment can only be inferred from trials performed in first-line, either upfront or after i.v. induction chemotherapy. One small trial, comparing cisplatin 100 mg/m 2 plus cyclophosphamide i.v. versus cisplatin 200 mg/m 2 plus etoposide i.p. did not show a survival advantage for the i.p. treatment [25] . However, the recently reported intergroup trial (0051), comparing i.v. cyclophosphamide plus i.v. cisplatin with i.v. cyclophosphamide plus i.p. cisplatin showed a significant survival advantage with less systemic toxicity for the group receiving i.p. cisplatin [42] . The prospective randomized phase III trial of the EORTC Gynecological Cancer Cooperative Group, evaluating the effect of i.p. cisplatin for consolidation in patients having achieved a surgically defined complete response after first-line platinumbased chemotherapy, is still ongoing [43] . Until these data are mature the value of i.p. treatment after i.v. cisplatin-based chemotherapy with regard to survival will remain uncertain. We therefore conclude that, although the application of i.p. chemotherapy in these circumstances is theoretically attractive, its routine use cannot be recommended as yet and should be restricted to research settings.
